[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Eetho Brands, Inc\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":90},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100639837","a-clinical-trial-of-an-herbal-liquid-supplement---dbps-for-managing-blood-pressure-100639837",false,"NCT07629570","A Clinical Trial of an Herbal Liquid Supplement - 'DBPS' for Managing Blood Pressure","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of DOSE for Blood Pressure Shot (DBPS) in Prehypertensive Subjects.","Inclusion Criteria:\n\n1. Men and women between the ages 18 and 65 years, inclusive, at the time of signing the informed consent.\n2. Seated clinic systolic blood pressure (SBP) in the range of 120 to 139 mm Hg and diastolic blood pressure (DBP) in the range of 80 to 89 mmHg confirming a prehypertensive state as per JNC 7 and WHO guidelines.\n3. In good general health as determined by a medical history, physical examination, vital signs, electrocardiogram (ECG), and routine clinical laboratory tests (hematology, clinical chemistry, urinalysis).\n4. Body Mass Index less than 30 kg\u002Fm2.\n5. Women of childbearing potential (WOCBP) must agree to use a highly effective method of contraception (e.g., oral contraceptives, intrauterine device, barrier methods with spermicide, surgical sterilization) from screening until the end of the study. Women who are postmenopausal (defined as amenorrhea for at least 12 consecutive months) or surgically sterile are eligible.\n6. Provide written informed consent to participate in the study after all procedures have been fully explained and questions answered.\n7. Willing and able to comply with all study procedures, visit schedules, and restrictions.\n\nExclusion Criteria:\n\n1. Diagnosed with Stage 1 Hypertension (SBP more than 139 mmHg or DBP more than 89 mmHg or Stage 2 Hypertension as per JNC 7 and WHO guidelines\n2. Evidence of secondary hypertension (e.g., renal artery stenosis, primary hyperaldosteronism, sleep apnea).\n3. History of significant cardiovascular disease, including but not limited to:\n\n   (i) Myocardial infarction, stroke, or transient ischemic attack within the past 6 months.\n\n   (ii) Symptomatic heart failure or left ventricular ejection fraction less than 40%.\n\n   (iii) Cases of class III and class IV congestive heart failure (CHF) as defined by the New York Heart Association.\n\n   (iv) Unstable angina pectoris or revascularization procedure within the past 3 months.\n\n   (v) Significant valvular heart disease or complex congenital heart disease by medical history.\n4. Use of any medications (prescription, over-the-counter, herbal supplements, certain vitamins\u002Fminerals) known to affect blood pressure or interfere with study product absorption\u002Fmetabolism within 14 days prior to the dosing visit, or unwillingness to stop them for the study duration.\n5. Organ Function Impairment:\n\n   (i)Impaired hepatic function (Alanine aminotransferase \\[ALT\\] or Aspartate aminotransferase more tan 2 times the upper limit of normal \\[ULN\\]).\n\n   (ii)Impaired renal function (serum creatinine level more than 132.6 μmol\u002FL or estimated Glomerular Filtration Rate \\[eGFR\\] less than 60 mL\u002Fmin\u002F1.73m2).\n\n   (iii) Serum potassium outside the normal range (less than 3.5 mmol\u002FL or more than 5.5 mmol\u002FL).\n6. History of uncontrolled diabetes mellitus (e.g., HbA1C level more than 7.0% and\u002For FBS more than 125mg\u002FdL or use of diabetes medications).\n7. Any chronic diseases that may interfere with study participation or pose additional risk to the subject.\n8. A tobacco smoker or user of nicotine products in the 6 months prior to screening.\n9. Excessive alcohol consumption (Men more than 14 drinks\u002Fweek and women more than 7 drinks\u002Fweek).\n10. History of substance abuse or dependency within the last 1 year.\n11. Women who are pregnant or lactating.\n12. History of hypersensitivity or contraindication to the test product (DBPS) or any of its components or placebo.\n13. Participation in another clinical research study involving an investigational product within 30 days prior to screening or during the current study.",true,"ALL","18 Years","65 Years",{"count":21,"type":22},198,"ESTIMATED","INTERVENTIONAL",[25],"NA","Prehypertension is a clinical condition characterized by systolic blood pressure (SBP) readings between 120 and 139 mmHg and\u002For diastolic blood pressure (DBP) readings between 80 and 89 mmHg, as per the Joint National Committee (JNC 7) and World Health Organization (WHO) guidelines. Individuals falling within this range do not yet meet the criteria for hypertension but are at a significantly elevated risk of progressing to full-blown hypertension and developing associated cardiovascular diseases such as heart attack and stroke. This stage is considered as a critical window for intervention, as timely and appropriate measures can potentially halt or delay the progression to more severe health issues.",[28],"Prehypertension",[30],"Elevated Blood Pressure","NOT_YET_RECRUITING","2026-06-01",{"date":34,"type":35},"2026-06-05","ACTUAL",{"date":37,"type":22},"2026-05-15",{"date":39,"type":22},"2026-08-30",{"name":41,"class":42},"Eetho Brands, Inc","INDUSTRY",4,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":16,"sex":51,"minAge":52,"maxAge":19,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":65,"locationsCount":4},"100585198","efficacy-of-cl22205-on-bone-mineral-density-and-menopausal-symptoms-100585198","NCT06899243","Efficacy of CL22205 on Bone Mineral Density and Menopausal Symptoms","The Effect of CL22205 on Bone Mineral Density and Menopausal Symptoms in Women: A Randomized, Double-blind, Placebo Controlled Clinical Trial","Inclusion Criteria:\n\n* Healthy females aged between 55 and 65 years with a Body mass index (BMI) of approximately 24 and 29 kg\u002Fm2.\n* Women with menopausal symptoms (modified Kupperman index scores 15-29), absence of menstrual cycle for past 12-months; follicle-stimulating hormone (FSH) \\> 30 mIU\u002FmL; estradiol \\\u003C 30 pg\u002FmL.\n* Subjects who are under standard supplementation of Vitamin D3 (cholecalciferol) and calcium carbonate.\n* Subjects with osteopenia (T score of spine between -1 and -2.5 in DEXA).\n* Must also be experiencing at least two symptoms of menopause, such as sleep disturbances, mood changes, fatigue and lack of energy, changes in sexual function, urinary changes, weight gain, or vaginal changes.\n* Subject understands the study procedures and provides signed informed consent to participate in the study.\n* Normal vital signs, including electrocardiogram (ECG) and laboratory evaluations (including clinical biochemistry, haematology, lipid profile, thyroid profile and complete urinalysis) within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator.\n\nExclusion Criteria:\n\n* Consumption of functional food or supplement that modifies body composition, during or 6 months prior to the study.\n* History of cerebrovascular disease, thrombo-embolic disorders, heart attack, or angina at any time or thrombophlebitis within the last 5 years.\n* Subjects on anti-coagulant or anti-platelet drugs on a daily basis for any conditions.\n* Presence of chronic diseases that prevent the performance of a physical exercise program (disabling arthropathies, moderate \u002F severe chronic lung disease, arrhythmias, etc.).\n* High alcohol intake (\\>2 standard drinks per day), or recreational drugs (such as cocaine, methamphetamine, marijuana, etc.) or psychiatric drug users.\n* Smokers or tobacco users.\n* Inability to understand informed consent.\n* Serious or terminal illnesses.\n* Fasting blood glucose level \\>125 mg\u002Fdl.\n* Subjects with a high blood pressure at screening (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥ 90 mmHg).\n* Subjects who had any hormonal therapy, metformin or any other herbal products in the past 3 months.\n* Hypothyroidism, hyperthyroidism, hyperprolactinemia, Cushing's syndrome and congenital adrenal hyperplasia, following a special diet for the past 3 months.\n* Taking drugs affecting insulin sensitivity or lipid and hormonal profiles, including glucocorticoids, ovulation-stimulating drugs, anti-obesity, anti-diabetes, anti-hypertensive, anti-estrogenic, anti-androgenic during the last 3 months (except the usual drugs of the subjects).\n* Active gall bladder disease, gynaecological (including hysterectomy) or breast surgery in the last 6 months.\n* Subjects who are being treated for liver cancer or cirrhosis, chronic renal failure, congestive heart failure.\n* Subjects with a systemic disease including tuberculosis, leucosis, collagenosis, multiple sclerosis or other autoimmune diseases.\n* History of breast, endometrial, other gynaecological cancer at any time or other cancer within the last 5 years.\n* History of hypersensitivity reactions attributed to investigational product (IP) or its components or related products.\n* History of positive hepatitis screening including Hepatitis B surface antigen or Hepatitis C virus (HCV) antibodies or subjects with human immunodeficiency virus (HIV) and \u002For syphilis.\n* History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol.\n* Participated in a clinical study with an investigational drug or biologic within the last 30 days.\n* Any condition that in opinion of the investigator, does not justify the subjects' participation in the study.","FEMALE","55 Years",{"count":54,"type":22},80,[25],"The purpose of this study is to evaluate the effect of CL22205 on bone mineral density and menopausal symptoms in women.",[58],"Menopausal Symptoms","2025-03-21",{"date":61,"type":35},"2025-03-27",{"date":63,"type":22},"2025-03-25",{"date":39,"type":22},{"name":41,"class":42},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":16,"sex":51,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":23,"phases":76,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":4},"100574569","efficacy-of-cl22205-to-improve-menstrual-discomfort-and-quality-of-life-100574569","NCT06760988","Efficacy of CL22205 to Improve Menstrual Discomfort and Quality of Life","A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of CL22205 to Improve Menstrual Discomfort and Quality of Life","Inclusion Criteria:\n\n* Oligomenorrheic females (Menstrual cycle duration between 36-45 days), aged between 25 and 35 years and with a Body Mass Index (BMI) between 20 to 29.9 kg\u002Fm2.\n* Subjects with maximum pain intensity ≥40 mm on a 100 mm VAS for at least 2 menstrual cycles before participating in the study.\n* Subjects with normal thyroid profile.\n* Subjects who are non-smokers and non-alcohol user.\n* Subject understands the study procedures and provides signed informed consent to participate in the study.\n* Females of childbearing potential who are sexually active must agree to use adequate non-hormonal contraception during the study.\n* Normal vital signs, including electrocardiogram (ECG) and laboratory evaluations (including clinical chemistry, hematology, and complete urinalysis) within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator.\n\nExclusion Criteria:\n\n* History of any gynaecological disorders which effects the study indication.\n* History of cerebrovascular disease, thrombo-embolic disorders, heart attack, or angina at any time or thrombophlebitis within the last 5 years, on anti-coagulant or anti-platelet drugs on a daily basis for any conditions.\n* Subjects who had any hormonal therapy, metformin or any other herbal products in the past 3 months.\n* Hypothyroidism, hyperthyroidism, hyperprolactinemia, Cushing's syndrome and congenital adrenal hyperplasia, following a special diet for the past 3 months, taking drugs affecting insulin sensitivity or lipid and hormonal profiles, including glucocorticoids, ovulation-stimulating drugs, anti-obesity, anti-diabetes, anti-hypertensive, anti-estrogenic, anti-androgenic during the last 3 months (except the usual drugs of the subjects).\n* Active gall bladder disease, gynaecological or breast surgery in the last 6 months.\n* Subjects underwent hysterectomy.\n* History of breast, endometrial, other gynaecological cancer at any time or other cancer within the last 5 years.\n* Pregnant and lactating mothers.\n* History of hypersensitivity reactions attributed to investigational product (IP) or its components or related products.\n* History of positive hepatitis, including Hepatitis B surface antigen or Hepatitis C virus (HCV) antibodies or subjects with human immunodeficiency virus (HIV) and \u002For syphilis.\n* History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol.\n* Participated in a clinical study with an investigational drug or biologic within the last 60 days.\n* Any condition that in opinion of the investigator, does not justify the subjects' participation in the study.\n* Subjects who are being treated for liver cancer or cirrhosis, chronic renal failure, congestive heart failure.\n* Subjects with a systemic disease including tuberculosis, leucosis, collagenosis, multiple sclerosis or other autoimmune diseases.\n* Subjects with a high blood pressure at screening (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥ 90 mmHg).\n* Consumption of recreational drugs (such as cocaine, methamphetamine, marijuana, etc.) or psychiatric drug users.","25 Years","35 Years",{"count":54,"type":22},[25],"The purpose of this study is to evaluate the efficacy of CL22205 to improve menstrual discomfort and quality of life in oligomenorrheic female subjects.",[79],"Menstrual Discomfort",[81],"Quality of life","2025-03-04",{"date":84,"type":35},"2025-03-07",{"date":86,"type":22},"2025-02-24",{"date":88,"type":22},"2026-01-10",{"name":41,"class":42},""]